Article
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Investigational new drugs - 1 Oct 2014
Izetti Patricia, Hautefeuille Agnes, Abujamra Ana Lucia, de Farias Caroline Brunetto, Giacomazzi Juliana, Alemar Bárbara, Lenz Guido, Roesler Rafael, Schwartsmann Gilberto, Osvaldt Alessandro Bersch, Hainaut Pierre, Ashton-Prolla Patricia
Abstract excerpt
TP53 mutation is a common event in many cancers, including pancreatic adenocarcinoma, where it occurs in 50-70 % of cases. In an effort to reactivate mutant p53 protein, several new drugs are being developed, including PRIMA-1 and PRIMA-1(Met)/APR-246 (p53 reactivation and induction of massive apoptosis). PRIMA-1 has been shown to induce apoptosis in tumor cells by reactivating p53 mutants, but its effect in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.